HPTN 061: Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM

HPTN 064: The Women’s HIV SeroIncidence Study

HPTN 069: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women

HPTN 073: Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities

HPTN 077: A Phase IIa Safety, Tolerability and Acceptability Study of an Investigational Injectable HIV Integrase Inhibitor, GSK1265744, for PrEP in HIV Uninfected Men and Women

HPTN 102 
A Phase 2 Study to Evaluate the Pharmacokinetics, Safety, and Acceptability and Use of Twice Yearly Long Acting Subcutaneous Lenacapavir for PreExposure Prophylaxis Among Women in the United States

The AMP Studies HVTN 703/HPTN 081 and HVTN 704/HPTN 085
AMP stands for Antibody Mediated Prevention which investigates if a broadly neutralizing antibody can protect people from HIV in the form of a vaccine.